Smith E V, Kolodny N H, Gragoudas E S, Egan K M, Finn S, D'Amico D J, Seddon J M
Howe Laboratory of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston 02114.
Invest Ophthalmol Vis Sci. 1990 May;31(5):993-7.
In a recent article a simple nuclear magnetic resonance (NMR) blood test was suggested for the detection of the presence of cancer. The test's sensitivity to uveal melanoma of both pre- and posttreatment status has been investigated. Cases in this study were 95 patients with uveal melanoma, and controls were 70 participants in an ongoing case control study of retinal eye disease being conducted at the Massachusetts Eye and Ear Infirmary. Proton NMR evaluations at 4.7 T (200 MHz) were performed on plasma obtained from EDTA and citrated blood samples. The average line-width values were calculated from each spectrum. Statistical analysis revealed that mean proton NMR line widths were essentially equal for patients with treated (18.7 Hz) and untreated tumors (18.4 Hz) and for controls (18.5 Hz). Results based on this data set suggest that proton NMR spectroscopy has little predictive power in the detection of uveal melanoma or in the monitoring of therapy.
在最近的一篇文章中,有人提出用一种简单的核磁共振(NMR)血液检测来检测癌症的存在。该检测对葡萄膜黑色素瘤治疗前和治疗后状态的敏感性已得到研究。本研究的病例为95例葡萄膜黑色素瘤患者,对照为70名正在马萨诸塞州眼耳医院进行的视网膜眼病病例对照研究的参与者。对从EDTA和枸橼酸化血液样本中获得的血浆进行了4.7 T(200 MHz)的质子NMR评估。从每个光谱计算平均线宽值。统计分析表明,治疗后肿瘤患者(18.7 Hz)、未治疗肿瘤患者(18.4 Hz)和对照组(18.5 Hz)的平均质子NMR线宽基本相等。基于该数据集的结果表明,质子NMR光谱在检测葡萄膜黑色素瘤或监测治疗方面几乎没有预测能力。